ZZYL(SH:600568)2024-05-16 12:15Group 1: Event Overview - The company participated in the "2024 Hubei Listed Companies Investor Online Reception Day" on May 16, 2024, from 14:30 to 16:00 via the P5W.net platform [2][3] - The event was attended by the company's board secretary, financial director, and relevant personnel for interactive communication with investors [3] Group 2: Key Investor Questions and Responses - Question 1: Progress on the research of Sulfate Yimucao Alkaloid and expected market launch timeline Response: As of the end of 2023, the project has completed Phase I clinical data review and is currently conducting Phase II clinical stability studies [4][7] - Question 2: Growth of hospital business and future plans Response: The company operates three hospitals and aims to expand operations, enhance departmental capabilities, and improve profit levels [5] - Question 3: Status of FDA application for Sulfate Yimucao Alkaloid and Phase II clinical trial details Response: The project is in Phase II clinical stability research, with reports indicating a trial size of 800 participants [6][7] - Question 4: Measures to address continuous losses despite high gross margins in hospital and medical device sectors Response: The company plans to transform pressure into motivation, focus on project expansion, and enhance operational efficiency to improve competitiveness [5][7] Group 3: Risk Warning - The company cautions that any forecasts regarding industry trends or strategic plans should not be interpreted as commitments or guarantees regarding future performance [8]